New York, NY (PRWEB) October 16, 2006 —
Heart valve disease will be the focus of the Third Annual Scientific Session of the Heart Valve Society of America (HVSA). The event, Valves in the Heart of the Big Apple V: Evaluation & Management of Valvular Heart Diseases 2007, will provide state-of-the-art information on diagnosis and treatment of this emerging public health problem. The session will be held from April 12 – 14, 2007 at the Crowne Plaza Hotel, New York City.
Valves in the Heart of the Big Apple is sponsored by the Weill Medical College of Cornell University and co-sponsored by HVSA, New York Cardiology Society of the New York State Chapter/American College of Cardiology and American Heart Association/Heritage Affiliate.
Valvular heart diseases are among the most prominent causes of heart failure and premature cardiac death. It is estimated that more than 15 million Americans have some type of heart valve abnormality, and in more than five million, the disease is moderate to severe. Three to four million will require surgery at some time in their lives. Valve diseases increase in frequency as people grow older. With the aging of the Baby Boom generation, valve diseases are emerging as an important public health concern.
Valves in the Heart of the Big Apple V: Evaluation and Management of Valvular Heart Diseases 2007 will provide state-of-the-art information for more than 500 cardiologists, cardiothoracic surgeons, other physicians, allied health professionals and non-physician researchers from the US and abroad.
The symposium will be conducted by nationally and internationally-recognized cardiologists, cardiothoracic surgeons, anesthesiologists, epidemiologists and allied health professionals specializing in the field.
Course features include:
- current criteria for surgical intervention;
- cell and molecular biology of valve and/or myocardial dysfunction in valve disease;
- generally accepted and recently emerging predictors of prognostically- important deterioration among common lesions;
- current approaches to preparation of the patient with valve disease for anesthesia;
- emerging data on the use of percutaneous techniques for valve repair and replacement, as well as the regulatory concerns related to development of these methods;
- emerging information on the role of pacemaker therapy for mitral regurgitation;
- the controversial role of drug prophylaxis for asymptomatic patients;
- the relative efficacy of surgical and catheter-based therapy for atrial fibrillation associated with mitral valve disease;
- predictive value of arrhythmias for sudden death after mitral valve surgery; the possible basis of ICD use;
- the emerging role of aortic valve repair for aortic valve diseases in association with aortic aneurysm;
- the relative efficacy of medical and surgical therapies for mitral regurgitation secondary to cardiomyopathy;
- the impact of age on morbidity and mortality in valve surgery; considerations for surgical candidacy;
- anti-coagulation strategy early and late after valve replacement; and,
- criteria for mitral valve surgery when mitral regurgitation is secondary to ischemic injury
Abstract submissions are being accepted through January 19, 2007.
HVSA (including the Heart Valve Trialists Society) was founded in November 2004 by nationally and internationally prominent cardiologists and cardiothoracic surgeons who work in the field of heart valve disease. Its mission is to promote research, educate medical professionals about the evaluation and treatment of heart valve diseases, serve as an informational resource for government, private industry, healthcare providers, the media and public, and, encourage and facilitate education of future heart valve disease specialists.
Membership is open to medical and allied health professionals involved/interested in the field, as well as individuals who work for corporations, academic and service institutions, and foundations interested in valvular heart disease.
View the conference brochure at http://www.heartvalvesocietyofamerica.org.
For more information, email email@example.com.